VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

live attenuated Brucella melitensis virB2 deletion mutant vaccine

Vaccine Information

Vaccine Name: live attenuated Brucella melitensis virB2 deletion mutant vaccine
Target Pathogen: Brucella spp.
Target Disease: Brucellosis
Vaccine Ontology ID: VO_0009195
Type: Live attenuated vaccine
Status: Research
Host Species for Licensed Use: Goat
Host Species as Laboratory Animal Model: Mus musculus (BALB/c mice); Capra hircus (pregnant goats)
Antigen: virB2 | virB2 deletion mutant
Preparation: Live attenuated unmarked deletion mutant of virB2 gene. (Kahl-McDonagh and Ficht, 2006)
Unmarked deletion mutant live attenuated vaccine strain BMDeltavirB2. (Kahl-McDonagh et al, 2006)
Description: Constructed unmarked deletion mutants of virB2 gene in Brucella melitensis as vaccine candidates. Efficacy: Provided less protection compared to Deltaasp24 mutants against heterologous challenge. Immune response: No direct association between protection and cytokine response was apparent. (Kahl-McDonagh and Ficht, 2006)
The vaccine candidate BMDeltavirB2 was evaluated in pregnant goats, the natural host species for Brucella melitensis. Efficacy: BMDeltavirB2 was considered safe as it did not cause abortion or colonize fetal tissues and was protective against abortion and infection in the majority of pregnant goats, though less efficacious than BMDeltaasp24. (Kahl-McDonagh et al, 2006)

Host Response

Goat Response

Challenge Protocol: Safety and efficacy were assessed by monitoring pathology, abortion, colonization of fetal and maternal tissues, and protection against challenge with wild-type Brucella melitensis 16M. (Kahl-McDonagh et al, 2006)
Efficacy: BMDeltavirB2 was considered safe as it did not cause abortion or colonize fetal tissues and was protective against abortion and infection in the majority of pregnant goats, though less efficacious than BMDeltaasp24. (Kahl-McDonagh et al, 2006)
Description: Safety and efficacy were assessed by monitoring pathology, abortion, colonization of fetal and maternal tissues, and protection against challenge with wild-type Brucella melitensis 16M. (Kahl-McDonagh et al, 2006)

Mouse Response

Host Strain: BALB/c
Immune Response: No direct association between protection and cytokine response was apparent. (Kahl-McDonagh and Ficht, 2006)
Challenge Protocol: Tested in BALB/c mice for protection against homologous and heterologous challenge infections. (Kahl-McDonagh and Ficht, 2006)
Efficacy: Provided less protection compared to Deltaasp24 mutants against heterologous challenge. (Kahl-McDonagh and Ficht, 2006)
Description: Tested in BALB/c mice for protection against homologous and heterologous challenge infections. (Kahl-McDonagh and Ficht, 2006)

References

Kahl-McDonagh and Ficht, 2006: Kahl-McDonagh MM, Ficht TA. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infection and immunity. 2006; 74(7); 4048-4057. [PubMed: 16790778].

Kahl-McDonagh et al, 2006: Kahl-McDonagh MM, Elzer PH, Hagius SD, Walker JV, Perry QL, Seabury CM, den Hartigh AB, Tsolis RM, Adams LG, Davis DS, Ficht TA. Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis. Vaccine. 2006 Jun 12; 24(24); 5169-77. [PubMed: 16697090].